B-CELL LYMPHOMA REFRACTORY
Clinical trials for B-CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cocktail targets deadly brain lymphoma
Disease control Recruiting nowThis early-phase trial tests whether adding the oral drug selinexor to standard chemotherapy can help people with relapsed or refractory B-cell non-Hodgkin lymphoma that has spread to the central nervous system. About 37 adults will receive the combination to find the safest dose…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC